Atopic Dermatitis | LEO Pharma | LP0133-1275
Pharmaceutical Company/Sponsor:
LEO Pharma
Code:
LP0133-1275
Title:
A Phase 2b, Double-blind, Randomised, 5-arm, Vehicle-controlled, Dose Ranging Trial to Evaluate the Efficacy and Safety of Twice Daily Topical Applications of Delgocitinib Cream 1, 3, 8, 20 mg/g for 8 Weeks in Adult Subjects With Mild to Severe Atopic Dermatitis.
Type:
Interventional
Phase:
2
Condition/Disease:
Atopic Dermatitis
Intervention(s)/Treatment(s):
Drug: Delgocitinib cream
Drug: Delgocitinib cream vehicle
Status:
Active, Not Recruiting
Link for Additional Information:
